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Abstract 
Context: Higher serum TSH levels, both within the reference range and in those with 
subclinical hypothyroidism (SCH), have been associated with increased risk of 
atherosclerosis and cardiovascular (CV) events in a number of cross-sectional and 
longitudinal studies.  
Objective: to evaluate blood thrombogenicity (BT) in patients post non-ST elevation 
acute coronary syndrome (NSTE-ACS) with relation to their thyroid function. 
Design, patients and outcome measure: Seventy patients one week after troponin 
positive NSTE-ACS who had been treated with optimal antiplatelet and secondary 
prevention therapy were studied. Patients with known thyroid disease or on 
medications affecting thyroid function were excluded. BT was assessed using the ex-
vivo Badimon perfusion chamber.  
Results: Serum TSH was associated with higher thrombus burden (β=0.30; p=0.01) 
independent of other well-established CV risk factors.  Patients with SCH (n=12; 
17%) had a higher thrombus burden than euthyroid individuals as evidenced by the 
area of the thrombus: mean (SD) [23,608 (10,498) vs 16,661 (10,902) µ2/mm, 
p=0.02]. However, this association was not evident when the analysis was limited to 
patients with serum TSH within the reference range. In addition, neither serum free 
T4 nor free T3 had any significant association with thrombus area.  
Conclusion: Serum TSH levels, particularly in the subclinical hypothyroid range, are 
associated with higher thrombus burden despite optimal recommended secondary 
prevention therapy following NSTE-ACS. This may explain the higher CV risk seen in 
SCH patients. Future trials to assess the effect of individualised anti-thrombotic as 
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well as thyroid hormone replacement therapy to reduce atherothrombotic risk in this 
population are needed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Introduction   
Subclinical hypothyroidism (SCH), a state of mild thyroid failure characterised by a 
raised serum thyroid stimulating hormone (TSH) level with normal thyroid hormone 
concentrations, is associated with increased risk of cardiovascular disease (CVD) 
and CVD-related mortality 1. Furthermore, higher TSH levels within the reference 
range are associated with an increased risk of myocardial infarction in patients with 
established cardiovascular disease 2. In addition, there is growing evidence that CVD 
patients with SCH have increased cardiac and all-cause mortality 3, 4. SCH has been 
associated with lipid abnormalities, atherosclerotic plaque progression and instability 
and endothelial dysfunction 5. However, the association of thyroid dysfunction after 
non-ST elevation acute coronary syndrome (NSTE-ACS) with blood thrombogenicity 
(BT) is unknown. We hypothesized that in the setting of NSTE-ACS, the presence of 
SCH increases blood thrombogenicity.  
Materials 
Patients: Patients with symptoms of myocardial ischaemia and elevated high 
sensitive cardiac troponin I levels (>0.1 μmol/L) on at least 2 occasions 12 hours 
apart and angiographically proven coronary artery disease (>50% stenosis in at least 
one major vessel) were recruited. In accordance with the current American Heart 
Association/European Society of Cardiology guidelines on NSTE-ACS management, 
all patients received 300mg loading and 75 mg daily maintenance dose of both 
aspirin and clopidogrel along with other three standard secondary prevention 
medications: hydoxymethyl co-enzyme A reductase inhibitor (HMG-CoA), 
angiotensin converting enzyme (ACE) inhibitor (or angiotensin receptor blocker) and 
a beta-blocker (or a calcium channel blocker as clinically indicated) 6, 7. This study 
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was approved by the Local Research Ethics Committee and all participants gave 
written informed consent. The study was conducted in accordance with the ethical 
principles of the declaration of Helsinki. 
Exclusion criteria: Patients with normal coronary angiogram, current smokers, those 
on antiplatelet or antithrombotic agents other than aspirin and clopidogrel, individuals 
with known thyroid dysfunction or on medications known to affect thyroid function 
such as amiodarone or lithium, coagulation abnormalities, anaemia (Hb<12g/dl), and 
those with malignancy or being investigated for malignancy were excluded. 
Assessment of platelet dependent thrombus formation: This was assessed 7 to 10 
days after the index event using the validated ex-vivo Badimon perfusion chamber 8. 
This model consists of three small Plexiglass chambers in series; each chamber was 
lined with a piece of porcine aorta stripped of the intimal layer to expose the 
underlying thrombogenic medial layer which simulates atherosclerotic plaque rupture 
leading to thrombus formation.  The first is a low shear chamber unit (inner lumen 
diameter: 2.0mm; vessel wall shear rate: 212/sec; average blood velocity: 5.3 
cm/sec; Reynolds number: 30) that simulates flow in a normal coronary artery and 
the next two are high shear units (inner lumen diameter: 1.0mm; vessel wall shear 
rate: 1690/sec; average blood velocity: 21.2 cm/sec; Reynolds number: 60) that 
simulate flow conditions in a moderately stenosed coronary artery. A peristaltic pump 
at the distal end drew blood directly from an intravenous catheter over the porcine 
aorta at a constant rate of 10 ml/minute for 5 min. The aortas with thrombi were fixed 
in 10% buffered formalin for 72 hours and stained with modified Masson trichrome 
stain. The stained thrombus was quantified by planimetry using a Leica DM2000 
microscope (Leica Microsystems, Weltzler, GmBH) under 10X magnification and the 
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Image ProPlus 4.0 software (Media cybernetics, MD, USA). Total thrombus area was 
calculated as mean of individual thrombus area in individual high shear chambers 
and expressed as μ2/mm. All the slides were analysed by one independent observer 
(GV) with intra-observer co-efficient of variation 4.3%. 
Biochemical analysis: Blood samples were taken immediately after the Badimon 
perfusion chamber study, 7 to 10 days after the index event. Serum samples were 
prepared after centrifuging at 1550g for 10 minutes. Samples were stored at -80° 
Celsius and thawed once prior to analysis. Serum creatinine, lipid levels, troponin I, 
haemoglobin, fibrinogen, platelet count and platelet volume were analysed by 
standard techniques. HbA1c (DCCT aligned) was measured by TOSOH Bioscience 
G8 analyser (TOSOH biosciences, CA, USA). Serum TSH (reference range 0.4 – 4.0 
mU/L), free T4 (reference range 9 – 25 pmol/L), free T3 (reference range 2.5 – 7.5 
pmol/L) and thyroid peroxidase (TPO) antibodies (positive if greater than 35 IU/ml) 
were measured by electrochemiluminescence immunoassay on the Roche cobas 
e602 (Roche Diagnostics, UK). P selectin and soluble CD40L were measured by 
ELISA methods (R&D systems, Abington,UK) and TNF alfa was measured by 
electrochemiluminescence methods (MSD, MD,USA). The within-day and between 
day co-efficient of variation for all tests were less than 5%. 
Patients with serum TSH above the reference range and serum free T4 levels within 
the reference range were classed as having SCH (n=12) whereas those with both 
TSH and free T4 within the reference range were categorised as being euthyroid 
(n=58). In addition, to ensure that the serum TSH abnormality was not transient, 
individuals with SCH had their levels rechecked a few months after their NSTE-ACS 
(median 4, range 2 – 14 months). This showed that 9 of 12 individuals were still in 
the SCH state, one person with the highest TSH of 23 mU/L had been commenced 
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on levothyroxine, one person had not had their thyroid function rechecked and one 
participant’s TSH had reverted back to within the reference range. None of the 
patients had overt hypothyroidism (FT4 < 9 pmol/L), hyperthyroidism (both overt and 
subclinical), nor had a low free T3 level.  
Statistical analysis:  Patients with SCH were compared to euthyroid individuals using 
unpaired t-test. Variables that were not normally distributed (serum TSH levels and 
thrombus area) were log transformed to normality prior to analysis. A multivariate 
regression analysis was performed with thrombus area as the dependent and 
established CV risk factors (age, gender, history of prior CVD, diabetes mellitus, 
hypertension, cerebrovascular disease, body mass index and LDL cholesterol levels) 
and serum TSH as independent variables. Secondary analyses utilising SCH as a 
categorical variable or FT4 or FT3 concentrations as a linear variable were also 
performed. Analyses were performed using SPSS version 21.0 (IBM Corp, NY, 
USA). Two-tailed significance was set at <0.05. 
 
Results 
Baseline Characteristics:  
SCH was identified in12 (17%) post NSTE-ACS patients. Baseline demographic, 
clinical, risk factor profile and laboratory characteristics were similar in both the SCH 
and euthyroid groups (Table 1) except, as expected, serum TSH level was 
significantly higher, FT4 levels lower and more individuals were positive for 
antibodies against TPO in the SCH group.  
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Thrombus area: 
NSTE-ACS patients with SCH had higher platelet dependent thrombus formation 
compared to euthyroid group: mean µ2/mm (SD) [23,608 (10,498) vs 16,661 (10,902) 
µ2/mm, p=0.02] (Table 1). A representative picture taken from typical patients in each 
thyroid status group can be seen in Figure 1. 
Predictors of thrombus area: 
Serum TSH level as a continuous variable was an independent predictor of thrombus 
area (β=0.30, p=0.01). Figure 2 (for web only) shows univariate association between 
serum TSH and thrombus area. Neither FT4 nor FT3 concentrations were found to 
have any independent association with total thrombus area (results not shown). 
In secondary analysis, SCH was an independent predictor of thrombus area (β=0.25, 
p=0.027). In addition, history of diabetes mellitus (β=0.47; p=0.001) and previous 
cerebrovascular disease (β=0.36; p=0.002) were also identified as independent 
predictors of thrombus area. One individual had serum TSH of 23.3 mU/L with 
normal FT4 level (14.0 pmol/L). We performed all analyses after excluding this 
individual and found results to be essentially unaltered (results not shown). 
Furthermore, analysis was performed after excluding the two individuals who either 
normalised TSH level subsequently or did not have their thyroid function rechecked. 
This showed that the results were essentially unchanged for thrombus area, 
although the strength of the difference was statistically weaker due to smaller 
number in the SCH group: mean µ2/mm (SD) 22,334 (5774) in SCH vs 16,661 
(10,902) in euthyroid group; p=0.08.  
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Discussion 
Higher blood thrombogenicity was related to increasing serum TSH levels which was 
significant in patients with SCH when compared to the euthyroid group despite all 
patients receiving optimal secondary prevention therapy including aggressive 
antithrombotic therapy. In addition, SCH was a significant predictor of thrombus 
burden independent of other well established cardiovascular risk factors such as 
diabetes mellitus and cerebrovascular disease. This finding may explain the higher 
cardiovascular risk seen in the SCH population. Moreover, the linear relationship 
between serum TSH and thrombus area in the post NSTE-ACS setting suggesting 
that the association may have a causal link although appropriately powered 
intervention studies alone will prove this. This study also demonstrates that 
prevalence of SCH in a carefully selected population is high in patients post NSTE-
ACS (17%).   
SCH has been associated with many CV risk factors such as increased serum lipid 
levels, diastolic hypertension, impaired endothelial function, increased arterial 
stiffness, and possibly altered coagulation parameters and elevated C-reactive 
protein levels 5. The Rotterdam study suggested that SCH is independently 
associated with atherosclerosis and with an increased incidence of myocardial 
infarction in the aging female population 9. Recent meta-analyses have also 
confirmed higher CV events and mortality in younger to middle aged adults with SCH 
10, 11. Furthermore, the 12-year mortality follow up in HUNT study demonstrated that 
high serum TSH levels within the reference range are associated with increased 
mortality from coronary heart disease in women 12. L-thyroxine therapy has been 
shown to positively affect endothelial function 13, reduce progression of angiographic 
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coronary artery disease in hypothyroid patients 14, improve atherogenic lipid profile15 
, and is associated with a reduced all-cause mortality as well as  fewer CVD events 
in younger individuals 16. Recently, it has been reported that mean platelet volume, a 
risk factor for CVD, is higher in SCH individuals and was positively correlated with 
TSH levels 17.  
As far as we are aware, BT in relation to thyroid function particularly patients with 
SCH in a post NSTE-ACS state has never been assessed before. The Badimon 
perfusion chamber system is a validated ex vivo model of vessel injury and 
thrombosis and has previously been used to evaluate the effects of novel 
antithrombotic agents in human subjects in different disease states 18,19. We have 
used this perfusion system to evaluate the effects of anti-platelet therapy on 
thrombus formation in various high risk population groups such as patients with 
established coronary artery disease and type 2 diabetes mellitus. This technique has 
been well validated in our laboratory 8, 20. The model enables the measurement of 
thrombus formation in native (non-anticoagulated) whole blood triggered by 
exposure to physiologically relevant substrate (collagen in tunica media), and under 
different rheological conditions mimicking those in narrowed blood vessels. 
Mechanisms that increase the risk of CV events in patients with established CVD 
and SCH are unknown. Hence our findings are novel and have the potential for 
further research in this high CV risk population. 
The main limitation of our study is its relatively small sample size particularly in the 
SCH group. Despite this, the SCH group were found to have a higher thrombus area 
independent of other traditional risk factors. Furthermore, we found a linear 
relationship between serum TSH levels and thrombus area that adds to the growing 
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evidence relating to a link between the two. The other limitation of this study, due to 
its observational nature, is that causality of thyroid status with higher thrombus 
burden cannot be assessed. In addition, it is unknown if higher thrombus burden is 
associated with increased future CV events. Finally, due to the carefully selected 
nature of participants for this study (exclusion of current smokers, those with 
anaemia, etc; outlined in detail in Methods), the results of this study may not be 
generalised to the wider SCH population post NSTE-ACS. For instance, smokers 
tend to have a lower serum TSH levels but have a higher CVD risk.  
In conclusion, this study has shown that post NSTE-ACS individuals with higher 
serum TSH levels and, in particular SCH, have higher thrombus burden despite 
optimal secondary prevention therapy which may explain their high CV risk. Future 
longitudinal studies are required to assess if this increased thrombus burden is 
indeed associated with adverse CV morbidity and mortality. Eventually, trials that 
assess the effect of individualised antithrombotic as well as thyroid hormone 
replacement therapy to reduce the atherothrombotic risk in patients with SCH post 
NSTE-ACS are required. 
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Legends to tables and figures: 
 
Table 1: Demographic and biochemical values of patients with SCH and 
Euthyroidism 
Figure 1. Picture of typical thrombus from patients with SCH and Euthyroidism 
Figure 2 (for web only). Univariate association between serum TSH levels and 
ex-vivo thrombus area in post non ST elevation acute coronary syndrome 
patients. 
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Table 1: Demographic and biochemical values of patients with SCH and 
Euthyroidism 
Characteristics (Mean ± SD) or 
Median (range) 
 
SCH (n=12) Euthyroid (n=58) p value 
Age (years)  
63.5 ± 10.0 62.4 ± 12.5 0.78 
Males n (%) 
9 (75) 48 (83) 0.53 
BMI (kg/m2)  
32.5 ± 6.8 31.3 ± 7.3 0.60 
Systolic Blood Pressure (mm Hg)  
131.5 ± 16.3 126.9 ± 19.6 0.44 
Diastolic Blood Pressure (mm 
Hg)  
74.9 ± 9.9 71.1 ± 9.4 0.21 
Resting Heart rate (beats/minute)  
63.9 ± 16.4 62.6 ± 14.2 0.79 
 
Risk factor profile: n (%) 
 
Hypertension  
Diabetes mellitus  
Previous CVD  
Previous CVA  
 
8 (66.7) 
5 (41.7) 
3 (25) 
1 (8.3) 
 
34 (58.6) 
27 (46.6) 
30 (51.7) 
7 (12.1) 
 
0.60 
0.76 
0.09 
0.71 
 
 
Laboratory data: (Mean ± SD) 
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Haemoglobin (g/dl) 
Platelets (x1000/mm3) 
Mean platelet volume (fL) 
Fibrinogen (g/l) 
Creatinine (µmol/l) 
HbA1c (%) 
hs CRP (mg/l) 
Troponin I (µg/l) 
Total cholesterol (mmol/L) 
LDL cholesterol (mmol/L) 
Free T4 (pmol/L) 
Free T3 (pmol/L) 
TSH (mU/L) median (range) 
TPO antibody >35 IU/ml n(%) 
P selectin (ng/ml) 
sCD40L (ng/ml) median (range) 
  
TNFalfa (ng/ml) 
13.9 ± 1.0 
268 ± 78.4 
8.6 ± 1.1 
4.6 ± 1.3 
113 ± 42.6 
6.1 ± 1.0 
7.4 ± 7.6 
10.2 ± 14.3 
3.8 ± 1.0 
1.7 ± 0.6 
14.1 ± 1.5 
4.8 ± 0.78 
4.94 (4.32 – 23.3) 
4 (33.3) 
61.2 ± 23.3 
1504.7 (309.5 – 
9368.3) 
9.4 ± 4.3 
13.7 ± 1.6 
243 ± 72.6 
9.0 ± 1.2 
4.1 ± 1.1 
100 ± 21.2 
6.5 ± 1.4 
7.5 ± 10.1 
6.16 ± 10.8 
3.5 ± 0.9 
1.7 ± 0.7 
15.6 ± 1.9 
4.8 ± 0.60 
1.85 (0.54 – 3.96) 
2 (3.4%) 
66.4 ± 26.2 
2532.1 (357.1 – 20727) 
 
8.5 ± 3.4 
    0.66 
0.30 
0.29 
0.48 
0.13 
0.37 
0.97 
0.46 
0.42 
0.92 
0.01 
0.79 
<0.001 
<0.001 
0.51 
0.18 
 
0.37 
Mean high shear mean thrombus 
area in µ2/mm (Mean ± SD) 
23,608 ± 10,498 
 
16,661 ± 10,902 
 
 
0.02  
 
 
* P value < 0.05 
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; CVA, 
cerebrovascular accident; hs CRP, high-sensitivity C-reactive protein; LDL, low 
density lipoprotein; TPO, thyroid peroxidase; sCD40L, soluble CD40 ligand; TNFalfa, 
tumour necrosis factor alfa. 
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Figure 1. Representative picture of thrombus from patients with SCH and 
Euthyroidism 
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Figure 2 (for web only). Univariate association between serum TSH levels and 
ex-vivo thrombus area in post non ST elevation acute coronary syndrome 
patients. 
 
 
 
r=0.41, p<0.01 
